Literature DB >> 24894774

The future of autologous stem cell transplantation in myeloma.

Frits van Rhee1, Sergio Giralt2, Bart Barlogie1.   

Abstract

Autologous stem cell transplantation (ASCT) has long been considered frontline therapy for newly diagnosed myeloma patients. This Spotlight examines the role of ASCT in the era of novel drugs and argues that ASCT should continue to be considered for eligible patients. A combination of novel drugs with ASCT in a sequential treatment approach can attain long-term survival and perhaps cure a subset of patients. ASCT will likely remain an important platform to develop curative strategies in the foreseeable future.
© 2014 by The American Society of Hematology.

Entities:  

Mesh：

Year:  2014        PMID： 24894774      PMCID： PMC4102706          DOI： 10.1182/blood-2014-03-561985

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  46 in total

1.  Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.

Authors:  Bart Barlogie; Guido Tricot; Erik Rasmussen; Elias Anaissie; Frits van Rhee; Maurizio Zangari; Athanasios Fassas; Klaus Hollmig; Mauricio Pineda-Roman; John Shaughnessy; Joshua Epstein; John Crowley
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

2.  Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

Authors:  Bart Barlogie; Guido J Tricot; Frits van Rhee; Edguardo Angtuaco; Ron Walker; Joshua Epstein; John D Shaughnessy; Sundar Jagannath; Vanessa Bolejack; Jennifer Gurley; Antje Hoering; David Vesole; Raman Desikan; David Siegel; Jayesh Mehta; Seema Singhal; Nikhil C Munshi; Madhav Dhodapkar; Bonnie Jenkins; Michel Attal; Jean-Luc Harousseau; John Crowley
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

3.  Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Authors:  Fenghuang Zhan; Bart Barlogie; Varant Arzoumanian; Yongsheng Huang; David R Williams; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Maurizio Zangari; Madhav Dhodapkar; John D Shaughnessy
Journal:  Blood       Date:  2006-10-05       Impact factor: 22.113

4.  Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.

Authors:  M L Grazziutti; L Dong; M H Miceli; S G Krishna; E Kiwan; N Syed; A Fassas; F van Rhee; H Klaus; B Barlogie; E J Anaissie
Journal:  Bone Marrow Transplant       Date:  2006-10       Impact factor: 5.483

5.  Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.

Authors:  Mauricio Pineda-Roman; Vanessa Bolejack; Varant Arzoumanian; Elias Anaissie; Frits van Rhee; Maurizio Zangari; Ron Walker; Klaus Hollmig; John D Shaughnessy; Joshua Epstein; Somashekar Krishna; John Crowley; Bart Barlogie
Journal:  Br J Haematol       Date:  2006-12-08       Impact factor: 6.998

6.  Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.

Authors:  Ronald Walker; Bart Barlogie; Jeffrey Haessler; Guido Tricot; Elias Anaissie; John D Shaughnessy; Joshua Epstein; Rudy van Hemert; Eren Erdem; Antje Hoering; John Crowley; Ernest Ferris; Klaus Hollmig; Frits van Rhee; Maurizio Zangari; Mauricio Pineda-Roman; Abid Mohiuddin; Shmuel Yaccoby; Jeffrey Sawyer; Edgardo J Angtuaco
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

7.  Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

Authors:  Paolo Corradini; Michele Cavo; Henk Lokhorst; Giovanni Martinelli; Carolina Terragna; Ignazio Majolino; Pinuccia Valagussa; Mario Boccadoro; Diana Samson; Andrea Bacigalupo; Nigel Russell; Vittorio Montefusco; Claudia Voena; Gosta Gahrton
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

8.  Clinical course of patients with relapsed multiple myeloma.

Authors:  Shaji K Kumar; Terry M Therneau; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; S Vincent Rajkumar; Rafael Fonseca; Thomas E Witzig; John A Lust; Dirk R Larson; Robert A Kyle; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2004-07       Impact factor: 7.616

9.  Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.

Authors:  Helgi J K van de Velde; Xiangyang Liu; Gang Chen; Andrew Cakana; William Deraedt; Martine Bayssas
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

10.  A comparison of allografting with autografting for newly diagnosed myeloma.

Authors:  Benedetto Bruno; Marcello Rotta; Francesca Patriarca; Nicola Mordini; Bernardino Allione; Fabrizio Carnevale-Schianca; Luisa Giaccone; Roberto Sorasio; Paola Omedè; Ileana Baldi; Sara Bringhen; Massimo Massaia; Massimo Aglietta; Alessandro Levis; Andrea Gallamini; Renato Fanin; Antonio Palumbo; Rainer Storb; Giovannino Ciccone; Mario Boccadoro
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245
View more
  24 in total

Review 1.  First line vs delayed transplantation in myeloma: Certainties and controversies.

Authors:  Annamaria Brioli
Journal:  World J Transplant       Date:  2016-06-24

2.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

3.  Haematological cancer: Optimizing the treatment of multiple myeloma.

Authors:  Gareth J Morgan; Frits van Rhee
Journal:  Nat Rev Clin Oncol       Date:  2014-10-28       Impact factor: 66.675

Review 4.  Minimal residual disease testing after stem cell transplantation for multiple myeloma.

Authors:  A M Sherrod; P Hari; C A Mosse; R C Walker; R F Cornell
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

Review 5.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

6.  Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

Authors:  Susan O'Brien; Manish Patel; Brad S Kahl; Steven M Horwitz; Francine M Foss; Pierluigi Porcu; Jeffrey Jones; Jan Burger; Nitin Jain; Kerstin Allen; Kerrie Faia; Mark Douglas; Howard M Stern; Jennifer Sweeney; Patrick Kelly; Virginia Kelly; Ian Flinn
Journal:  Am J Hematol       Date:  2018-10-20       Impact factor: 10.047

7.  A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.

Authors:  M Martino; G Tripepi; G Messina; I D Vincelli; G Console; A G Recchia; M Gentile; S Molica; F Morabito
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

8.  Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.

Authors:  Yogesh S Jethava; Alan Mitchell; Joshua Epstein; Maurizio Zangari; Shmuel Yaccoby; Erming Tian; Sarah Waheed; Rashid Khan; Xenofon Papanikolaou; Monica Grazziutti; Michele Cottler-Fox; Nathan Petty; Douglas Steward; Susan Panozzo; Clyde Bailey; Antje Hoering; John Crowley; Jeffrey Sawyer; Gareth Morgan; Bart Barlogie; Frits van Rhee
Journal:  Clin Cancer Res       Date:  2016-11-03       Impact factor: 12.531

9.  Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway.

Authors:  Luyuan Zhang; Sinan Sun; Yumin Wang; Yongzhen Mo; Fang Xiong; Shanshan Zhang; Zhaoyang Zeng; Wei Xiong; Guiyuan Li; Hao Chen; Can Guo
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

10.  Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data.

Authors:  Adrián Mosquera Orgueira; Marta Sonia González Pérez; José Ángel Díaz Arias; Beatriz Antelo Rodríguez; Natalia Alonso Vence; Ángeles Bendaña López; Aitor Abuín Blanco; Laura Bao Pérez; Andrés Peleteiro Raíndo; Miguel Cid López; Manuel Mateo Pérez Encinas; José Luis Bello López; Maria Victoria Mateos Manteca
Journal:  Leukemia       Date:  2021-05-18       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.